APLS Q2 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$178M-10.6% YoY

Gross Profit

$164M92.1% margin

Operating Income

-$33M-18.6% margin

Net Income

-$42M-23.6% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$821M

Total Liabilities

$665M

Stockholders' Equity

$156M

Cash & Equivalents

$371M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$200M	-10.6%
Gross Profit	$164M	$176M	-6.7%
Operating Income	-$33M	-$29M	-13.1%
Net Income	-$42M	-$38M	-11.9%

Revenue Segments

Product

$171M96%

Licensing And Other Revenue

$7M4%